Axsome Therapeutics, Inc (AXSM) Stock Price

AXSMStock

$205.48+73.32%52W

Market Cap$10.76B

P/E—

PEG Ratio—

Div yield—

Beta0.86

AXSM Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-0.06%

Price vs S&P 500 (4W)-15.35%

VGM Score51.16

Book Value / Share (Quarterly)$1.59

P/TBV (Annual)410.04x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)133.68%

Cash Flow / Share (Quarterly)$-1.38

Price vs S&P 500 (YTD)0.50%

Gross Margin (TTM)93.24%

Net Profit Margin (TTM)-24.68%

EPS (TTM)$-3.76

10-Day Avg Trading Volume0.65M

EPS Excl Extra (TTM)$-3.76

EPS (Annual)$-3.68

ROI (Annual)-118.68%

Gross Margin (Annual)92.56%

Net Profit Margin (5Y Avg)-1038.72%

Cash / Share (Quarterly)$6.12

Revenue Growth QoQ (YoY)45.54%

ROA (Last FY)-50.57%

Revenue Growth TTM (YoY)56.87%

EBITD / Share (TTM)$-3.53

ROE (5Y Avg)-345.24%

Operating Margin (TTM)-23.96%

Cash Flow / Share (Annual)$-2.63

P/B Ratio135.83x

P/B Ratio (Quarterly)151.20x

Net Income / Employee (Annual)$-198,000

EV / Revenue (TTM)14.42x

Net Interest Coverage (TTM)-27.02x

ROA (TTM)-27.05%

EPS Incl Extra (Annual)$-3.68

Current Ratio (Annual)2.11x

Quick Ratio (Quarterly)1.30x

3-Month Avg Trading Volume0.86M

52-Week Price Return73.32%

Revenue / Employee (TTM)$839,500

Tangible BV / Share (Quarterly)$0.88

P/S Ratio (Annual)17.72x

Asset Turnover (Annual)0.68x

52-Week High$260.19

Operating Margin (5Y Avg)-1009.22%

EPS Excl Extra (Annual)$-3.68

CapEx CAGR (5Y)57.20%

Tangible BV CAGR (5Y)18.82%

26-Week Price Return11.18%

Quick Ratio (Annual)1.99x

13-Week Price Return-12.09%

Total Debt / Equity (Annual)3.25x

Current Ratio (Quarterly)1.43x

Enterprise Value$11.20B

Asset Turnover (TTM)1.10x

Book Value / Share Growth (5Y)-24.82%

Revenue / Employee (Annual)$690,300

Pretax Margin (Annual)-28.77%

Cash / Share (Annual)$6.43

3-Month Return Std Dev38.16%

Net Income / Employee (TTM)$-207,200

ROE (Last FY)-503.89%

Net Interest Coverage (Annual)-37.09x

EPS Basic Excl Extra (Annual)$-3.68

Receivables Turnover (TTM)3.26x

Total Debt / Equity (Quarterly)2.43x

EPS Incl Extra (TTM)$-3.76

ROI (TTM)-70.42%

P/S Ratio (TTM)14.57x

Pretax Margin (5Y Avg)-1038.72%

Revenue / Share (Annual)$12.83

Tangible BV / Share (Annual)$0.20

Forward P/E85.73x

Price vs S&P 500 (52W)55.01%

Year-to-Date Return12.46%

5-Day Price Return-4.77%

EPS Normalized (Annual)$-3.68

ROA (5Y Avg)-70.30%

Net Profit Margin (Annual)-28.69%

Month-to-Date Return-5.78%

Cash Flow / Share (TTM)$-4.39

EBITD / Share (Annual)$-3.43

Operating Margin (Annual)-27.74%

LT Debt / Equity (Annual)0.93x

ROI (5Y Avg)-108.06%

LT Debt / Equity (Quarterly)1.42x

EPS Basic Excl Extra (TTM)$-3.76

P/TBV (Quarterly)274.14x

P/B Ratio (Annual)71.94x

Inventory Turnover (TTM)1.87x

Pretax Margin (TTM)-24.61%

Book Value / Share (Annual)$1.16

Price vs S&P 500 (13W)-14.88%

Beta0.86x

Revenue / Share (TTM)$14.99

ROE (TTM)-255.60%

52-Week Low$112.90

vGradeD

gGradeB

mGradeC

vgmGradeC

AXSM Earnings Surprise History

Q2 25-0.97est. -1.09

Q3 25-0.94est. -0.88

Q4 25-0.56est. -0.73

Q1 26-1.26est. -0.86

Q2 26-0.99est. -0.78

AXSM Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.30

4.29

Industry Peers — Pharmaceuticals(571)

Symbol	Value Score	Growth Score	Momentum Score	Price
AXSMAxsome Therapeutics, Inc	D	B	C	$205.48
LLYEli Lilly & Co.	D	B	B	$1233.66
JNJJohnson & Johnson	D	C	B	$273.14
ABBVABBVIE INC.	D	C	B	$265.79
MRKMerck & Co., Inc.	D	C	A	$156.45
NVSNovartis AG	C	C	C	$159.98
AZNAstraZeneca PLC	C	B	C	$169.66
NVONovo-Nordisk A/S	B	C	C	$48.66
ABTAbbott Laboratories	C	C	B	$116.13
PFEPfizer Inc.	C	D	C	$28.57
VRTXVertex Pharmaceuticals Inc	D	C	B	$552.85
BMYBristol-Myers Squibb Co.	B	B	B	$67.92
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$46.02
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$52.07
REGNRegeneron Pharmaceuticals Inc	C	C	B	$833.56
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	C	$18.35
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$38.10
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	C	$376.37
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$62.07
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$240.08
ZTSZOETIS INC.	B	C	D	$77.29
INSMInsmed, Inc.	F	A	C	$123.89
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$36.47
UTHRUnited Therapeutics Corp	C	C	C	$518.53
GMABGenmab A/S ADS	C	C	B	$34.36
VTRSViatris Inc. Common Stock	B	C	B	$16.72
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$260.23
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$252.99
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$80.40
CORTCorcept Therapeutics Inc.	F	C	A	$123.57
BMRNBioMarin Pharmaceuticals Inc	C	C	C	$66.12
ARWRArrowhead Research Corporation	D	A	B	$88.88
ELANElanco Animal Health Incorporated Common Stock	C	B	B	$25.09
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	$512.16
CYTKCytokinetics Inc.	F	D	B	$77.46
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.36
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$63.57
ABVXAbivax SA American Depositary Shares	—	—	C	$117.93
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.34
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$368.02
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PTGXProtagonist Therapeutics, Inc	F	B	A	$150.59
SYRESpyre Therapeutics, Inc. Common Stock	—	—	A	$107.36
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.86
TGTXTG Therapeutics, Inc.	D	B	A	$55.42
ALKSAlkermes Inc. plc	D	C	B	$49.21
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$113.35
ORKAOruka Therapeutics, Inc. Common Stock	F	—	A	$101.82
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	$161.68
COGTCogent Biosciences, Inc. Common Stock	F	—	B	$36.80
TVTXTravere Therapeutics, Inc. Common Stock	F	B	A	$67.01

About Axsome Therapeutics, Inc

Axsome Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel therapies for central nervous system disorders with limited existing treatment options. The company's pipeline includes four late-stage candidates: AXS-05, AXS-07, AXS-12, and AXS-14, addressing multiple indications in neurology and psychiatry. Axsome targets underserved patient populations where unmet medical needs remain high.